Company intelligence / Profile preview

Shanghai Jinzhu Information Technology

Shanghai, Shanghai Shi, China

Ownership: Private
Development stage: Other

Overview

Shanghai Xinyi Jinzhu Pharmaceutical has at least one approved small molecule drug, neostigmine methylsulfate, targeting acetylcholinesterase for flatulence and potentially other indications in nervous system and immune-related diseases. No detailed clinical results are available in the search results.

Therapeutic areas: GastroenterologyNeurologyOncologyImmunology
Modalities: Small molecule drug
Industry: Biotech

Beyond the preview

Go deeper on Shanghai Jinzhu Information Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Jinzhu Information Technology.

Explore the full profile